Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
$10.58
-1.5%
$12.17
$10.47
$29.12
$154.03M0.6771,576 shs60,670 shs
HeartBeam, Inc. stock logo
BEAT
HeartBeam
$1.25
-40.4%
$71.92
$1.20
$3.48
$45.98M-0.59107,350 shs118,715 shs
Pulmonx Corporation stock logo
LUNG
Pulmonx
$2.59
-0.4%
$3.42
$2.50
$9.37
$104.67M0.52306,192 shs250,540 shs
Nyxoah SA stock logo
NYXH
Nyxoah
$7.48
+0.1%
$7.11
$5.55
$11.87
$254.43M1.6575,663 shs39,777 shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
-1.49%-3.11%-5.54%-29.61%-58.23%
HeartBeam, Inc. stock logo
BEAT
HeartBeam
-8.32%-15.88%-25.80%-36.99%-51.56%
Pulmonx Corporation stock logo
LUNG
Pulmonx
-0.38%+0.78%-22.69%-62.30%-59.15%
Nyxoah SA stock logo
NYXH
Nyxoah
+0.13%-4.47%-4.71%+8.88%+7.32%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
4.1009 of 5 stars
3.82.00.03.62.41.70.6
HeartBeam, Inc. stock logo
BEAT
HeartBeam
1.5749 of 5 stars
3.53.00.00.00.60.80.0
Pulmonx Corporation stock logo
LUNG
Pulmonx
3.283 of 5 stars
3.33.00.00.03.33.30.6
Nyxoah SA stock logo
NYXH
Nyxoah
3.1995 of 5 stars
3.55.00.00.01.60.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
3.50
Strong Buy$20.0089.04% Upside
HeartBeam, Inc. stock logo
BEAT
HeartBeam
3.00
Buy$8.00542.57% Upside
Pulmonx Corporation stock logo
LUNG
Pulmonx
2.63
Moderate Buy$11.53344.98% Upside
Nyxoah SA stock logo
NYXH
Nyxoah
3.00
Buy$14.5093.85% Upside

Current Analyst Ratings Breakdown

Latest BEAT, LUNG, ANIK, and NYXH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/22/2025
Pulmonx Corporation stock logo
LUNG
Pulmonx
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$6.50 ➝ $4.15
5/12/2025
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$20.00 ➝ $19.00
5/1/2025
Pulmonx Corporation stock logo
LUNG
Pulmonx
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $15.00
5/1/2025
Pulmonx Corporation stock logo
LUNG
Pulmonx
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$10.00 ➝ $9.00
5/1/2025
Pulmonx Corporation stock logo
LUNG
Pulmonx
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$17.00 ➝ $17.00
4/21/2025
Nyxoah SA stock logo
NYXH
Nyxoah
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $14.00
4/17/2025
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$21.00
4/16/2025
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/8/2025
Nyxoah SA stock logo
NYXH
Nyxoah
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
$119.91M1.27$0.09 per share112.59$10.51 per share1.01
HeartBeam, Inc. stock logo
BEAT
HeartBeam
N/AN/AN/AN/A$0.06 per shareN/A
Pulmonx Corporation stock logo
LUNG
Pulmonx
$83.79M1.24N/AN/A$2.17 per share1.19
Nyxoah SA stock logo
NYXH
Nyxoah
$4.89M52.10N/AN/A$3.60 per share2.08
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
-$56.38M-$3.88N/AN/AN/A-41.28%-7.22%-5.64%8/6/2025 (Estimated)
HeartBeam, Inc. stock logo
BEAT
HeartBeam
-$19.45M-$0.68N/AN/AN/A-358.33%-278.76%N/A
Pulmonx Corporation stock logo
LUNG
Pulmonx
-$56.39M-$1.44N/AN/AN/A-65.27%-63.69%-34.94%7/30/2025 (Estimated)
Nyxoah SA stock logo
NYXH
Nyxoah
-$64.10M-$2.13N/AN/AN/A-1,571.39%-63.37%-46.67%8/5/2025 (Estimated)

Latest BEAT, LUNG, ANIK, and NYXH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Nyxoah SA stock logo
NYXH
Nyxoah
-$0.49-$0.63-$0.14-$0.63$1.64 million$1.12 million
5/13/2025Q1 2025
HeartBeam, Inc. stock logo
BEAT
HeartBeam
N/A-$0.18N/A-$0.18N/AN/A
5/7/2025Q1 2025
Pulmonx Corporation stock logo
LUNG
Pulmonx
-$0.37-$0.36+$0.01-$0.36$22.03 million$22.54 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
N/AN/AN/AN/AN/A
HeartBeam, Inc. stock logo
BEAT
HeartBeam
N/AN/AN/AN/AN/A
Pulmonx Corporation stock logo
LUNG
Pulmonx
N/AN/AN/AN/AN/A
Nyxoah SA stock logo
NYXH
Nyxoah
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
N/A
5.73
4.53
HeartBeam, Inc. stock logo
BEAT
HeartBeam
N/A
5.45
5.46
Pulmonx Corporation stock logo
LUNG
Pulmonx
0.38
4.97
4.29
Nyxoah SA stock logo
NYXH
Nyxoah
0.22
3.59
3.35

Institutional Ownership

CompanyInstitutional Ownership
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
91.53%
HeartBeam, Inc. stock logo
BEAT
HeartBeam
7.77%
Pulmonx Corporation stock logo
LUNG
Pulmonx
91.04%
Nyxoah SA stock logo
NYXH
Nyxoah
N/A

Insider Ownership

CompanyInsider Ownership
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
9.64%
HeartBeam, Inc. stock logo
BEAT
HeartBeam
18.04%
Pulmonx Corporation stock logo
LUNG
Pulmonx
6.80%
Nyxoah SA stock logo
NYXH
Nyxoah
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Anika Therapeutics Inc. stock logo
ANIK
Anika Therapeutics
30014.34 million12.96 millionOptionable
HeartBeam, Inc. stock logo
BEAT
HeartBeam
1,70033.81 million27.71 millionNot Optionable
Pulmonx Corporation stock logo
LUNG
Pulmonx
25040.26 million37.52 millionOptionable
Nyxoah SA stock logo
NYXH
Nyxoah
11034.06 millionN/ANot Optionable

Recent News About These Companies

Brokers Set Expectations for Nyxoah FY2026 Earnings
Nyxoah SA (NYXH) Q1 2025 Earnings Call Transcript
Publication relating to transparency notifications

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Anika Therapeutics stock logo

Anika Therapeutics NASDAQ:ANIK

$10.58 -0.16 (-1.49%)
As of 06/30/2025 04:00 PM Eastern

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

HeartBeam stock logo

HeartBeam NASDAQ:BEAT

BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors. It also provides traditional and extended Holter, pacemaker, international normalized ratio, implantable loop recorder, and other implantable cardiac device monitoring services. It serves cardiologists, electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, such as cardiac monitoring, imaging, scientific consulting, and data management services for drug and medical device trials. Its centralized services comprise electrocardiogram, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The company also focuses on manufacturing, testing, and marketing of cardiac devices and blood glucose monitoring devices, as well as offers contract manufacturing services. BioTelemetry, Inc. was founded in 1994 and is headquartered in Malvern, Pennsylvania.

Pulmonx stock logo

Pulmonx NASDAQ:LUNG

$2.59 -0.01 (-0.38%)
As of 06/30/2025 04:00 PM Eastern

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Nyxoah stock logo

Nyxoah NASDAQ:NYXH

$7.48 +0.01 (+0.13%)
As of 06/30/2025 04:00 PM Eastern

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.